Z6·尊龙凯时「中国」官方网站z6尊龙

Beijing, China – From January 13 to January 15, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 8th Fuwai Aortic Diseases Treatment Symposium held in Beijing Fuwai Hospital, and displayed several devices including CRONUS™ Surgical Stent-Graft System ("CRONUS™"), Hercules™-T Low Profile Stent Graft and delivery system ("Hercules™-T"), and Castor™ Branched Aortic Stent Graft and delivery system ("Castor™").

As the aortic diseases are getting more complex and occurring at higher age, the application of hybrid procedure in treating aortic diseases is gaining increased attention and higher recognition and has become a new area full of chance and challenges. Focused on hybrid procedure, the Fuwai Symposium demonstrated the major advancement in the treatment of aortic diseases in recent years. Specifically, the symposium covered hot topics such as big data and evidence-based analysis in the field of aortic diseases, anesthesia and perioperative management, as well as relevant clinical and fundamental researches, through penal discussions and operation broadcasting.

On January 14, Professor Zaiping Jing of Shanghai Changhai Hospital of the Second Military Medical University delivered a speech on the advancement of endovascular minimally invasive treatment of ascending aortic dissection. He pointed out, the Castor™ system in-house developed by MicroPort® Endovascular has epoch-making significance in the endovascular treatment. Castor™ is the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. Castor™ employs an easy-to-use unibody design, including a main body and a left subclavian branch graft to avoid type III endoleaks. In 2015, Castor™ was granted by the China Food and Drug Administration ("CFDA") a special fast-track procedure for innovative medical devices to gain CFDA approval, which is expected to significantly shorten the approval time. Professor Jing also mentioned that he looks forward to seeing the market launch of Castor™ to benefit more patients.

After two days of rich discussions, the symposium wrapped up on January 15. During that period, many attendees were attracted to visit MicroPort® Endovascular booth in which it displayed the main features and operating procedures of several kinds of thoracic aortic products, enabling the visitors to get a deeper understating in Hybrid procedure and MicroPort® Endovascular products. MicroPort® Endovascular will continue to stick to innovative product R&D to build a brand reflecting our branding ideology "the Patient Always Comes First" with outstanding quality.